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Abstract: The incidence of gestational diabetes is increasing. As gestational diabetes is associated 
with adverse pregnancy outcomes, and has long-term implications for both mother and child, 
it is important that it is recognized and appropriately managed. This review will examine the 
pharmacological options for the management of gestational diabetes, as well as the evidence for 
blood glucose monitoring, dietary and exercise therapy. The medical management of gestational 
diabetes is still evolving, and recent randomized controlled trials have added considerably to our 
knowledge in this area. As insulin therapy is effective and safe, it is considered the gold standard 
of pharmacotherapy for gestational diabetes, against which other treatments have been compared. 
The current experience is that the short acting insulin analogs lispro and aspart are safe, but there 
are only limited data to support the use of long acting insulin analogs. There are randomized 
controlled trials which have demonstrated efﬁ  cacy of the oral agents glyburide and metformin. 
Whilst short-term data have not demonstrated adverse effects of glyburide and metformin on 
the fetus, and they are increasingly being used in pregnancy, there remain long-term concerns 
regarding their potential for harm.
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Background
Gestational diabetes (GDM) is deﬁ  ned as “carbohydrate intolerance with onset or 
ﬁ  rst recognition during pregnancy”.1 Large studies have found that GDM occurs in 
2.2%–8.8% of pregnancies, depending on the ethnic mix of the population and the 
criteria used for diagnosis.2 In some speciﬁ  c populations however, the incidence can 
be considerably higher. The incidence of GDM is increasing, in parallel to the increase 
in type 2 diabetes. Essentially, women at risk of type 2 diabetes are at risk of GDM.
During pregnancy, an increase in insulin resistance occurs. Euglycemia is 
maintained through a compensatory increase in insulin secretion. The key factor which 
results in the development of gestational diabetes appears to be a failure to compensate 
with increased insulin secretion.3 As the increase in insulin resistance is greatest in the 
third trimester, GDM usually develops going into this period. Therefore, screening 
for GDM usually occurs around 24–28 weeks into the pregnancy. The diagnosis is 
made with an oral glucose tolerance test, though the criteria vary around the world 
(Table 1). Risk factors for the development of GDM include obesity, older age, family 
history, previous history of GDM or poor obstetric outcomes, ethnicity, polycystic 
ovary syndrome and as more recently noted, hypertension.4,5
The major signiﬁ  cance of GDM is that it is associated with adverse pregnancy out-
comes. Macrosomia, shoulder dystocia with its attendant risks of brachial plexus injury 
and clavicle fracture, and neonatal hypoglycemia are the serious complications which 
most commonly occur.6–11 Jaundice, polycythemia, respiratory distress, and hypocalce-
mia have also been reported. Additionally, there are some data that suggest an increase 
in fetal malformation and perinatal mortality.7,12–15 The above risks can be minimized 
with good glycemic control and judicious obstetric care. Cesarean sections are also 
more common, and GDM is associated with a higher risk of pre-eclampsia.9–11Vascular Health and Risk Management 2009:5 154
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Exposure of the fetus to hyperglycemia may also 
predispose the child to a diabetes phenotype in later life. This 
has been elegantly demonstrated by the long-term follow-up 
of the offspring of Pima Indian mothers.16,17 Offspring who 
were born to mothers who were already diabetic when 
pregnant had a 45% likelihood of type 2 diabetes by the age 
of 20–24, whereas it was 8.6% amongst those with mothers 
who only developed diabetes after pregnancy (ie, were 
prediabetic). Amongst sibships discordant for exposure to 
hyperglycemia, the sibling exposed to hyperglycemia had 
a considerably higher risk of subsequent diabetes, suggesting 
that genetic factors were not predominantly responsible for 
the difference in diabetes incidence. Since then, numerous 
other observational studies have shown that the offspring 
of diabetic pregnancies have a higher risk of developing a 
diabetes phenotype.18,19 There is also concern that this leads 
to an intergenerational effect, with GDM promoting diabetes 
in the offspring, with perpetuation of the vicious cycle when 
the offspring herself develops GDM, thereby predisposing 
the grandchild to the development of diabetes as well.20 It is 
unknown however, what degree of hyperglycemia, or indeed 
if it is related metabolic disturbances, which increases the 
risk of diabetes to the offspring.
Additionally, the diagnosis of GDM indicates that the 
mother has a predisposition to diabetes. In most cases, this 
is type 2 diabetes. In the longest follow-up of women who 
have had GDM 36% of women had developed diabetes within 
22–28 years (by WHO criteria).21 This was in a predominantly 
white population in Boston from the 1960s. Evidence from 
more contemporary populations is that the likelihood of 
subsequent diabetes may be substantially higher.22 Women 
who have had GDM account for a signiﬁ  cant burden of the 
population prevalence of diabetes. It has been estimated 
that up to one third of women with diabetes, had a GDM 
pregnancy earlier in their life,2 though this was not evident 
in a recent survey of women with type 2 diabetes.23
This review will focus on the medical management of 
GDM, in particular self monitoring of blood glucose and 
diabetes education, dietary therapy and physical activity, 
pharmacotherapy, and post-partum management. For an 
excellent discussion of the obstetric management of GDM, 
I will refer the reader to the review by Conway.24
Diabetes education, self-monitoring 
of blood glucose, dietary therapy, 
and exercise
Self-care is an important component of the management of 
GDM. Therefore it is commonplace for the diabetes care 
team to provide the women with information and education 
to facilitate self-care. This includes information regarding 
GDM, self-monitoring of blood glucose, dietary counseling, 
and advice regarding healthy lifestyle measures post-partum. 
The involvement of a dietician and diabetes educator 
experienced in the care of women with GDM will facilitate 
these areas of management.
Blood glucose monitoring
Women with GDM should perform home blood glucose 
monitoring. Blood glucose levels are usually monitored in 
the fasting state and 1–2 hours after meals. Treatment to 
post-prandial targets results in superior pregnancy outcomes 
compared to pre-prandial targets.25 The recommended treat-
ment targets vary from country to country (Table 2). These 
are largely consensus-based as the risk of complications is 
continuous and there are no obvious thresholds above which 
the risk markedly increases.
The initial intervention usually entails dietary advice, 
individualized if possible, and given by a dietitian. Lifestyle 
measures can provide adequate control in the majority of 
cases. If glucose targets are not adequately met by lifestyle 
measures, and perhaps a review of dietary intake, then 
Table 1 Diagnostic criteria for GDM
Glucose load Glucose tolerance test (mmol/L) Abnormal values for diagnosis
Fasting 1 hour 2 hours 3 hours
ADA 75 g 5.3 10 8.6 Two or more
100 g 5.3 10 8.6 7.8 Two or more
ADIPS 75 g 5.5 8.0 One
CDA 75 g 5.3 10.6 8.9 Two or more = GDM
One value = IGT of pregnancy
WHO 75 g 7.0 11.1 One
Abbreviations: ADA, American Diabetes Association; ADIPS, Australasian Diabetes in Pregnancy Society; CDA, Canadian Diabetes Association; GDM, gestational diabetes 
mellitus;   WHO,   World Health Organisation.Vascular Health and Risk Management 2009:5 155
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pharmacotherapy should be introduced. This usually means 
the commencement of insulin.
Rather than basing the need for insulin on glycemic 
parameters alone, some have advocated the combined use 
of ultrasound assessment of fetal abdominal circumference 
in combination with blood glucose levels. When the fetal 
abdominal circumference was  70th percentile, a higher 
glucose threshold for initiating insulin therapy did not result in 
an increase in fetal morbidity or macrosomia.26 This protocol 
allowed more women to avoid insulin therapy.
Dietary therapy
It is generally accepted that dietary therapy is the corner-
stone of treatment of GDM. Therefore all women with 
GDM should receive counseling from a specialist dietitian. 
Recommendations are individualized after a dietary assess-
ment of each patient. The aim is to achieve normoglycemia 
whilst providing the required nutrients for normal fetal 
growth and maternal health. A secondary aim is to prevent 
excessive maternal weight gain, particularly in women who 
are overweight or have gained excess weight in pregnancy.
There are few trials examining the efﬁ  cacy of dietary 
therapy for GDM, However, a cluster randomized controlled 
study has provided support for Medical Nutrition Therapy 
(MNT) for GDM, as recommended by the American Diabetes 
Association (ADA) (2004). In this study, 215 women 
with GDM were seen at sites randomized to deliver either 
MNT or standard care.27 Fewer subjects in the MNT group 
required insulin (24.6% vs 31.7%, p = 0.05) and there was 
a trend to fewer women having a glycated hemoglobin 
(HbA1c)  6% (8.1% vs 13.6%, p = 0.25). The ADA states 
that all women should receive individualized counseling 
to provide adequate calories and nutrients to meet the 
needs of pregnancy and consistent with the blood glucose 
goals (fasting  105 mg/dl [5.8 mmol/L], 1 hr  155 mg/dl 
[8.6 mmol/L], and 2 hrs  130 mg/dl [7.2 mmol/L]). For 
obese women, a 30%–33% calorie restriction to approxi-
mately 25 kcal/kg actual weight per day is recommended. 
Carbohydrate should be restricted to 35%–40% of calories.
There are also data to support low carbohydrate diets in 
pregnancy, and for the carbohydrate to be of low glycemic 
index. In a nonrandomized study, women with GDM on 
a diet comprising less than 42% carbohydrate, had lower 
post-prandial glucose levels, were less likely to require insu-
lin, and had a lower incidence of large for gestational age.28 
A small study which randomized pregnant women to low 
glycemic index (GI) or high GI diets found that the former 
resulted in lower glucose levels, a blunting of the pregnancy 
associated rise in insulin resistance, and lower birthweight.29 
In another study of GI, women assigned to a low GI diet 
during pregnancy gave birth to infants who were lighter 
(3408 ± 78 g vs 3644 ± 90 g) and had a lower incidence of 
large for gestational age, compared to women given a high 
GI diet.30 Both diets comprised 55% carbohydrate. Whilst 
the latter studies were not speciﬁ  cally performed in women 
with GDM, they suggest that the concept of GI is valid in 
pregnancy, and it would be appropriate to recommend low 
GI carbohydrate to women with GDM.
Additional dietary measures are usually based upon the 
general recommendations for diabetes mellitus. A reduction 
in simple carbohydrates and fat intake is advisable. Emphasis 
is given to spreading the dietary intake over six meals 
daily, with three main meals and three snacks, in order 
to avoid large carbohydrate loads at any time. Except for 
saccharin, which can cross the placenta and is therefore not 
recommended, other noncaloric sweeteners may be used in 
moderation.
Physical activity
In people with type 2 diabetes, there is ample evidence 
that regular physical activity enhances insulin sensitivity, 
facilitates weight loss, and thereby improves glucose control. 
Several small studies have examined whether regular exercise 
is also beneﬁ  cial in the management of GDM Jovanavic-
Petersen randomized 19 women with GDM to a regime of 
diet alone, or diet with 20 minutes of supervised aerobic 
training three days per week for six weeks.31 This modest 
amount of physical activity resulted in lower fasting glucose 
levels, lower glucose responses to a glucose challenge, and 
a lower HbA1c. Another study randomized 29 women with 
GDM to 30 minutes of exercise at 70% estimated maximal 
heart rate, 3–4 times per week, or control.32 There was a trend 
to improved glucose levels in those who exercised, which did 
not reach signiﬁ  cance. There were no differences in neonatal 
outcomes. Measures of cardiorespiratory ﬁ  tness however, 
improved. A study of 32 women randomized to circuit type 
exercise three times a week or control, found that resistance 
training resulted in lower postprandial glucose levels, and a 
delay in the requirement of insulin.33 Amongst women with 
a prepregnancy BMI   25, those who were in the exercise 
arm were less likely to require insulin.
Therefore, it seems reasonable to recommend that when 
there is no medical or obstetric contraindication, women 
with GDM should maintain a sensible level of light and 
moderate intensity physical activity until the latter stages 
of the pregnancy. The above studies provide reassurance Vascular Health and Risk Management 2009:5 156
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that moderate intensity activities such as walking for 
20–30 minutes each day, and attendance at antenatal exercise 
classes can be safely encouraged, and that modest improve-
ments in glycemic control might be achieved.
Insulin therapy for gestational diabetes
When treatment targets are not achieved by dietary means, 
then insulin is required. A basal-bolus regimen of insulin 
gives the most effective glucose control, and produces 
better fetal outcomes than a twice daily regime.34 Prandial 
fast-acting insulin is administered to control post-prandial 
hyperglycemia, and bedtime basal insulin is given if there is 
fasting hyperglycemia. In some cases, an additional morn-
ing injection of basal insulin may further improve glycemic 
control. As the level of insulin resistance varies from person 
to person, it is common practice to commence the woman 
on small doses of insulin, and then to increase the doses at 
frequent intervals until target glucose levels are attained.
The required dosage of insulin usually increases gradually 
over the third trimester of pregnancy. Towards the end of the 
pregnancy, insulin requirements can drop. This may be an 
early indicator of placental insufﬁ  ciency. Frequent review 
and titration of the insulin dosage is recommended. Unlike 
the situation for women with pre-existing type 1 diabetes 
however, signiﬁ  cant hypoglycemia is uncommon in women 
with insulin-treated GDM. Nonetheless the woman should 
be advised regarding appropriate hypoglycemia prevention 
and management measures.
For many years, fast-acting (regular) insulin, and 
intermediate-acting (isophane) insulin have been the 
preferred insulins for the treatment of GDM. Human insulin 
does not normally cross the placenta, though antibody bound 
animal insulin has been reported to do so.35 However, it has 
been shown by36 Jovanovic that it is maternal glucose con-
trol, rather than maternal anti-insulin antibody levels which 
inﬂ  uence birthweight.36 Human insulin is considered safe 
in pregnancy as years of experience has not suggested an 
increase in fetal complications as a consequence of its use.
There is now increasing evidence that the newer rapid 
acting insulin analogs lispro and aspart are also safe in 
pregnancy, and indeed, they are commonly used. Although 
there was an initial small uncontrolled report which sug-
gested that Lispro may have teratogenic effects when used 
in type 1 diabetic pregnancy,37 this has not been borne out 
in subsequent studies. No increase in pregnancy complica-
tions have been found in observational studies where lispro 
was used, in either women with GDM38,43 or pre-existing 
diabetes.38–43 There are few reports regarding the use of aspart 
in pregnancy. However, a large randomized controlled trial 
comparing aspart with regular human insulin in 322 pregnant 
women with type 1 diabetes has been performed.44 Com-
parable birth outcomes were found between the two arms, 
suggesting that aspart is as safe and effective as human 
insulin.
With respect to GDM, there have been several small 
randomized studies comparing the use of rapid acting insulin 
analogues with regular insulin. They have all demonstrated that 
the rapid acting analogues are as effective as regular insulin 
in the treatment of GDM, with comparable, if not favorable, 
outcomes (Table 3). In one study, aspart was detected in the 
cord blood for one subject.45 However, as it was not detected 
in other subjects, the authors postulated that this was due to the 
disruption of the uterine-placental barrier during delivery, when 
the mother had been receiving an aspart infusion. As yet there 
have been no reports of the use of glulisine in pregnancy.
Data regarding the long-acting insulin analogs are less 
clear than for rapid-acting analogs. There are a number of 
case reports and small case series of glargine being utilized 
without the development of pregnancy complications. The 
majority of these have been in patients with type 1 dia-
betes. There are also data from a total of 48 women with 
GDM.46,47 To date no randomized controlled studies have 
been published. Concerns have been expressed about the 
use of glargine in pregnancy, because of its potential effect 
on mitogenesis, mediated by its high afﬁ  nity to the IGF-1 
receptor, which is six times that of natural insulin48,49 Whilst 
insulin detemir has a lower binding afﬁ  nity to the IGF-1 
receptor than natural insulin, there is even less information 
regarding its use in pregnancy.
Long-acting insulin analogs, particularly glargine, are 
increasingly being used in women with type 1 diabetes, and they 
are often continued through the pregnancy. Although their safety 
has not been proven, it is often rationalized that a change in the 
basal insulin will result in deterioration in glycemic control, and 
therefore the risk of continuing glargine is less than the risk from 
changing insulins. However, until their safety in pregnancy can 
be clearly established, the initiation of long-acting insulin analog 
therapy in women with GDM cannot be recommended.
Table 2 Recommended glucose targets
Fasting 1 hr postprandial 2 hr postprandial
ADA 5.8 8.6 7.2
ADIPS 5.5 8.0 7.0
CDA 5.3 7.8 6.7
Abbreviations: ADA, American Diabetes Association; ADIPS, Australasian Diabetes 
in Pregnancy Society; CDA, Canadian Diabetes Association.Vascular Health and Risk Management 2009:5 157
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Oral antidiabetic agents 
in gestational diabetes
There is controversy regarding the use of oral hypoglycemic 
agents during pregnancy. Most government drug agencies 
have not approved their use in pregnancy, and major specialty 
diabetes organizations recommend that oral agents be ceased 
if the woman had been taking them pre-pregnancy53–55 There 
have now however, been randomized trials conducted with 
both glyburide and metformin which have not demonstrated 
short term harm to the pregnancy.
Glyburide (Glibenclamide)
American authors have stated that glyburide has replaced 
insulin as ﬁ  rst line pharmacological treatment of GDM in many 
practices.56 This has largely occurred on the basis of a random-
ized controlled trial where 404 women with GDM were treated 
with glyburide (up to 20 mg/day) or insulin57 In this study, the 
level of glycemic control achieved was the same in both groups 
(mean glucose concentration during treatment with glyburide 
5.9 ± 0.9 mmol/L compared to 5.9 ± 1.0 mmol/L in insulin 
group). Only 4% of women treated with glyburide achieved 
inadequate control and required a switch to insulin. No dif-
ferences in large for gestational age, macrosomia, neonatal 
hypoglycemia, admission to neonatal intensive care, or fetal 
anomalies were observed. The incidence of maternal hypogly-
cemia was lower in the glyburide group (2% vs 20%).
Additionally, a number of nonrandomized or retrospec-
tive studies examining the treatment of GDM with glyburide 
have been reported (Table 4). In general, these indicate that 
glyburide is effective in achieving glycemic control in the 
majority of patients. Most, but not all, suggest that glyburide is 
as safe as insulin for the fetus. A meta-analysis which included 
the above studies as well as others examining women with 
pre-existing diabetes, with 745 glyburide exposed pregnancies 
and 637 treated with insulin, has been performed.65 This study 
found that glyburide did not increase the risk of macrosomia, 
large for gestational age, or neonatal hypoglycemia, but did 
not examine more serious consequences such as perinatal 
mortality or congenital anomalies. Several studies have 
examined factors which predict failure of glyburide to achieve 
adequate glycemic control. Higher glucose levels, either in the 
glucose tolerance test upon which GDM was diagnosed, or on 
self-monitoring, and early dietary failure have been found to 
be associated with glyburide failure.60,58 These ﬁ  ndings lead 
to the logical conclusion that subjects with more severe GDM 
are more likely to require insulin.
Further evidence supporting the safety of glyburide for the 
fetus comes from a study using an in vitro perfusion, where it 
was not found to cross the placenta in signiﬁ  cant amounts.66 
However, another in vitro study has found transplacental trans-
fer of glyburide.67 In the Langer randomized controlled trial, 
glyburide was not detected in the cord blood of the neonates and 
cord insulin levels were similar between the two groups.57
Metformin
A number of studies have provided conﬂ  icting information 
regarding the safety of metformin use in type 2 diabetic 
pregnancy.68–70 There are studies which have used metformin 
during pregnancy in women with polycystic ovary syndrome, 
without any noticeable adverse effects on the fetus.71 There are 
few publications of its use in GDM, and these are dominated 
by the Metformin in Gestational Diabetes (MiG) Study.
The MiG Study randomized 751 women with GDM to 
treatment with insulin or metformin.72 The women in the 
metformin arm were treated with supplemental insulin if the 
maximal dose of metformin, 2500 mg daily, failed to meet 
Table 3 Randomized trials comparing treatment of GDM with rapid acting insulin analogs and regular human insulin
Author, year Subjects Effect on HbA1c Effect on hypos Other comments
Lispro Aspart Regular
Jovanovic et al 199950 19 – 23 Lower 3rd 
trimester HbA1c 
with Lispro
Fewer hypos with 
lispro
Less 1 hr postprandial 
hyperglycemia with lispro
Mecacci et al 200351 25 – 24 Not reported Not reported 1 hr postprandial glucose 
higher with regular insulin
Pettitt et al 200745 – 14 13 No difference More minor, but 
not major hypos 
with aspart
Post-prandial glucose proﬁ  le 
and maternal c-peptide 
lower with aspart
Di Cianni et al 200752 33 31 32 No difference No subjects had 
hypos
1 hr postprandial glucose and 
birthweight higher in regular 
insulin subjects
Abbreviation: HbA1c, glycated hemoglobin.Vascular Health and Risk Management 2009:5 158
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Management of gestational diabetes
the glucose targets. The primary outcome variable was a 
composite of neonatal hypoglycemia, respiratory distress, 
need for phototherapy, birth trauma, Apgar score less than 7, 
or prematurity. There was no difference in the primary out-
come between the two groups (metformin 116 [32%] events, 
insulin 119 events [32.2%], RR 1.0 [0.9–1.1], p = 0.95). 
Interestingly fetal death and malformations were not a com-
ponent of the primary outcome; however, 19 events in the 
metformin group were classiﬁ  ed as serious fetal or neonatal 
adverse events (including 11 congenital anomalies) compared 
to 23 events in the insulin arm (including 18 congenital 
anomalies and one fetal death). None of these events were 
adjudged by the data and safety monitoring committee to be 
treatment related and there were no serious adverse events 
associated with the use of metformin. Additionally, more 
women using metformin indicated that their treatment was 
acceptable compared to those on insulin. From these results, 
the authors have suggested that metformin is a safe and effec-
tive treatment for GDM.
Several small studies comparing metformin to insulin for 
the treatment of GDM have also been performed (Table 5). 
Two have concluded that metformin is as effective as insulin 
for glycemic control in GDM, and that it is safe. However, 
one study, a randomised controlled trial, was underpowered 
to realistically address the effectiveness and safety of metfor-
min in GDM.73 In another study, a retrospective case control 
study, subjects treated with insulin had a greater degree of 
initial glucose intolerance, so the comparison was of limited 
validity.74 A third study comprised a retrospective cohort 
which included a mixture of both GDM and women with 
Type 2 diabetes seen from 1966–1991. It found an increase 
in stillbirth and perinatal mortality, as well as pre-eclampsia 
amongst those treated with metformin, compared to women 
treated with insulin or sulphonylureas. However, as there 
was no evaluation of glycemic control early in pregnancy, 
and more women on metformin had pre-existing type 2 
diabetes, the groups do not appear to be well matched. It is 
quite possible that the adverse ﬁ  ndings in this study are due to 
more women in the metformin group having a greater severity 
of hyperglycemia early in the pregnancy.
Long-term concerns regarding 
glyburide and metformin therapy 
for GDM
Although the above randomized trials have demonstrated non-
inferiority of glyburide and metformin in achieving glycemic 
control, and satisfactory birth outcomes compared to insulin 
therapy, concerns must remain as long-term issues have not 
yet been addressed. Repeated episodes of GDM are associated 
with the earlier development of diabetes, and this has been 
postulated to be due to the increased stress that the β-cells 
are exposed to with each pregnancy.75 By treating the mother 
with glyburide, it is possible that this accentuates β-cell stress 
and accelerates their decline, whereas insulin therapy would 
conversely provide a degree of relief to the β-cells. Therefore 
glyburide has the potential to result in earlier development of 
maternal diabetes, and long-term follow-up of the mothers 
are needed to alleviate this concern.
In contradistinction, metformin reduces insulin resistance 
and hepatic gluconeogenesis, which theoretically would be 
beneﬁ  cial for the preservation of β-cell function. In subjects 
with type 2 diabetes, the ADOPT Study has demonstrated 
that metformin is superior to glyburide in this regard.76 As 
there is transplacental passage of metformin,77,78 its effect 
on fetal insulin resistance might even provide further beneﬁ  t 
in light of data of insulin resistance and insulin secretory 
defects in offspring of diabetic pregnancies.19 However, any 
pharmacological agent which crosses the placenta must be 
viewed with caution as there always remains the possibil-
ity of unexpected long-term effects. Metformin alters gene 
expression in mice livers and has been demonstrated to have 
an antiproliferative effect through reductions in cyclin D1 and 
activation of AMP kinase.79 The programming and develop-
mental effects of these on a fetus are unknown. Furthermore, 
metformin can promote the development of lactic acidosis, 
which surely must be a concern in situations of fetal distress. 
Whilst 18-month follow-up data on 126 offspring of women 
with polycystic ovary syndrome treated with metformin dur-
ing pregnancy have not revealed any deﬁ  ciencies in growth 
or motor-social development, this may be too short a time 
frame for potential programming effects of metformin to 
become evident.80
In view of the above concerns regarding the potential of 
glyburide and metformin to have long-term effects on the 
mother and child, I would recommend caution with their 
use in the treatment of GDM. A subgroup of infants from 
the MIG Study are currently being followed up.72 It may be 
circumspect to await the ﬁ  ndings from this follow-up study 
before metformin can be considered safe for the routine 
treatment of GDM.
Other oral antidiabetic agents 
for gestational diabetes
There is one study which randomized women with GDM to 
treatment with insulin, glyburide, or acarbose.61 Forty two 
percent of the acarbose subjects failed to achieve adequate Vascular Health and Risk Management 2009:5 160
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Management of gestational diabetes
glycemic control and ultimately required insulin therapy. The 
incidence of large for gestational age was 10.5%, compared 
to 3.7% for insulin and 25% for glyburide (p = 0.07). The 
rate of neonatal hypoglycemia (5.3%) was similar to insulin 
(3.7%), but lower than glyburide (33%) (p = 0.006). Whilst 
this study is inadequately powered to demonstrate safety 
of acarbose, it is not absorbed from the gut, and therefore 
would be unlikely to affect the fetus. However it is of low 
potency and insulin therapy will often need to be introduced. 
Furthermore, the high frequency of gastrointestinal side 
effects experienced by people with type 2 diabetes suggests 
that any future role of acarbose, even if subsequent studies 
conﬁ  rm safety, will be limited.
There are no studies using glitazones in pregnancy. 
Transplacental transfer occurs,67,81 and until studies dem-
onstrating safety are performed, they should be avoided in 
pregnancy.
Evidence that treatment 
of gestational diabetes improves 
pregnancy outcomes
The strongest evidence that treatment of GDM is of beneﬁ  t 
comes from the Australian Carbohydrate Intolerance Study 
(ACHOIS) in Pregnant Women.82 In this randomized con-
trolled trial, 1000 women fulﬁ  lling the 1985 WHO criteria 
for “gestational glucose intolerance” were recruited. These 
subjects had a fasting glucose up to 7.7 mmol/dl and a 2 hour 
level between 7.8 mmol/L and 11.1 mmol/dl. They were 
randomized to receive treatment for GDM, including dietary 
advice, blood glucose monitoring, and insulin as required, or 
standard pregnancy care. Those receiving standard care were 
unaware that they had GDM. In the treatment group, the aim 
was to maintain a fasting glucose level of  5.5 mmol/L, and 
2 hour post-prandial reading  7.0 mmol/L. With this, there 
was a 1% incidence of serious perinatal outcomes (death, 
shoulder dystocia, fracture, and nerve palsy) compared to 
4% amongst women provided with standard pregnancy 
care only (adjusted risk reduction 0.33, p = 0.01). Fewer 
neonates in the treatment group were large for gestational 
age, and there was no difference in the incidence of small for 
gestational age infants. There was no difference in the rate 
of cesarean section. Preeclampsia occurred less frequently in 
the intervention group (12% vs 18%, adjusted risk reduction 
0.7, p = 0.02). One other important ﬁ  nding of this study was 
that intensively treated women had better quality of life and 
lower rates of depression.
Prior to ACHOIS, a large number of other studies had 
been performed to ascertain if treatment of GDM is of beneﬁ  t. 
These studies were largely retrospective, unrandomized, or 
lacked power to detect differences in serious adverse perinatal 
outcomes and will not be listed here. However, one large 
retrospective cohort study of 116,303 pregnancies, merits 
discussion. Because of changes in the diagnostic criteria for 
GDM over the years, Beischer (1996) was able to examine 
perinatal mortality amongst women who would have been 
diagnosed as having GDM by contemporary criteria, but were 
not considered to have GDM at the time, and were therefore 
untreated. The perinatal mortality rate was 2.6% in these 
women with ‘mild GDM’ in the 1970s, compared to 0.7%, 
in the 1980s after routine treatment had been introduced for 
this group. Their perinatal mortality rate was 2.3 times that 
of women with normal glucose tolerance. In the 1980s, with 
routine treatment for women with mild GDM, their outcomes 
were not different to women with normal glucose tolerance. 
It therefore seems likely that the decreased mortality rate was 
at least in part a consequence of treatment of GDM, rather 
than only to other improvements in obstetric outcome.
Post-partum management 
of gestational diabetes
The medical management of gestational diabetes should 
not conclude with the delivery of the fetus. Although 
hyperglycemia usually resolves with the conclusion of the 
pregnancy, women who have had GDM are at high risk of 
developing diabetes later in life. Apart from the development 
of diabetes, women who have had GDM have an adverse 
cardiac risk proﬁ  le, including the metabolic syndrome.83,84 
A higher prevalence of cardiovascular disease that occurs at 
a younger age, independent of the metabolic syndrome and 
type 2 diabetes has also been demonstrated.83
In view of the above, it is important that the woman who 
has had GDM receive counseling and support to reduce her 
long-term risk of diabetes. Screening for diabetes, at regular 
intervals, is recommended by a number of diabetes societies.4,85 
This is important for the early diagnosis of diabetes, to facilitate 
the prevention of complications. Furthermore, if the woman is 
of reproductive age, the pre-pregnancy recognition of diabetes 
is vital so that early pregnancy conditions can be optimized to 
prevent diabetes fetopathy. Issues speciﬁ  c to pre-existing dia-
betes in pregnancy include tight glycemic control and adequate 
folate supplementation.53,54 Additionally, post partum evalua-
tion and management of reversible cardiovascular risk factors 
such as smoking, obesity, hypertension, and hyperlipidemia 
should be undertaken.
There is evidence that lifestyle modiﬁ  cation, aiming for a 
5%–7% reduction in body weight, is effective in preventing Vascular Health and Risk Management 2009:5 162
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or delaying the development of diabetes in people with 
impaired glucose tolerance. Both the Diabetes Prevention 
Program86 and the Finnish Diabetes Prevention Study87 
demonstrated this, with an intensive intervention including 
lifestyle coaches, strict supervised exercise regimes and 
caloric restriction. As 15% of the women in the Diabetes 
Prevention Program and Diabetes Prevention Study had 
GDM, similar measures should be recommended to women 
after they have had GDM. However, it is unclear if less 
intensive interventions can be effective in this population. To 
date, small short-term studies focusing on dietary counseling 
alone, or a combination of behavioral strategies with weekly 
exercise classes, have not demonstrated an improvement 
in glucose tolerance.88,89 In part, this is probably due to the 
real life challenges of maintaining motivation for healthy 
lifestyle change amongst young women at a time that they 
are having to deal with young children, return to work, and 
further education. Nonetheless, there are undisputed ben-
eﬁ  ts to healthy eating and regular physical activity so these 
activities should be encouraged.
Summary and conclusions
Gestational diabetes is a common disorder which in the 
majority of cases, should initially be managed by dietary 
measures. These include a restriction in fat and simple car-
bohydrate intake, regular distribution of meals, carbohydrate 
foods favoring those with low glycemic index, and caloric 
restriction for those who are obese. Moderate physical 
activity should be encouraged. Fasting and post-prandial 
glucose testing is necessary for monitoring and guidance 
of therapy.
Where dietary measures are inadequate to achieve gly-
cemic targets, insulin should be introduced. Insulin is still 
the mainstay of pharmacological treatment of GDM, and this 
is ideally administered in a basal bolus regimen. The rapid 
acting analogs lispro and aspart are considered safe, but the 
safety of the long-acting analogs are yet to be determined. 
Whilst there are studies demonstrating short-term safety of 
glyburide and metformin during pregnancy, I suggest that 
they be reserved for situations where implementation of insu-
lin therapy is impractical or not possible. After all, we know 
that insulin therapy is safe and usually effective. ACHOIS 
has shown that it is acceptable to the majority of women. 
By eschewing insulin, doctors may actually be treating their 
own perceived fear of injections, rather than providing the 
best therapy to the patient. Based on our current information, 
insulin is still the best option, with the least potential for 
long-term risk to the mother and child.
With good medical and obstetric care, the risks to the 
pregnancy should be minimal. However, a woman with GDM 
is a woman at high risk of future diabetes. Therefore after the 
pregnancy, healthy lifestyle measures should be encouraged 
to minimize the likelihood of developing diabetes, and 
regular screening for diabetes should be undertaken.
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